Ftse Mib
36.207,55
-0,17%
DAX
20.990,84
0,45%
S&P 500
5.996,66
1,00%
NASDAQ
19.630,20
1,51%
Bitcoin
105.222,77
2,03%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Vaxart Inc (VXRT) Vaxart Inc (VXRT) Notizie

VXRT

Vaxart (VXRT)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:VXRT
DataOraFonteTitoloSimboloCompagnia
14/01/202519:40AllPennyStocks.comThis California-Based Biotech Found Massive Success Following DSMB ApprovalNASDAQ:VXRTVaxart Inc
14/01/202514:00GlobeNewswire Inc.Vaxart Highlights Progress of COVID-19, Norovirus and Influenza ProgramsNASDAQ:VXRTVaxart Inc
14/01/202501:55GlobeNewswire Inc.Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical TrialNASDAQ:VXRTVaxart Inc
31/12/202422:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VXRTVaxart Inc
17/12/202422:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VXRTVaxart Inc
02/12/202422:01GlobeNewswire Inc.Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine CandidateNASDAQ:VXRTVaxart Inc
19/11/202414:00GlobeNewswire Inc.Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VXRTVaxart Inc
13/11/202422:23Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VXRTVaxart Inc
13/11/202422:01GlobeNewswire Inc.Vaxart Provides Business Update and Reports Third Quarter 2024 Financial ResultsNASDAQ:VXRTVaxart Inc
07/11/202414:00GlobeNewswire Inc.Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13NASDAQ:VXRTVaxart Inc
24/10/202414:00GlobeNewswire Inc.Vaxart to Showcase its COVID-19 and Norovirus Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2024NASDAQ:VXRTVaxart Inc
15/10/202414:00GlobeNewswire Inc.Vaxart to Present Norovirus Data at IDWeek 2024 Underscoring Commitment to Address Significant Unmet NeedNASDAQ:VXRTVaxart Inc
08/10/202422:06Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VXRTVaxart Inc
30/09/202422:12GlobeNewswire Inc.Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine CandidateNASDAQ:VXRTVaxart Inc
28/08/202414:00GlobeNewswire Inc.Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical DysplasiaNASDAQ:VXRTVaxart Inc
08/08/202422:01GlobeNewswire Inc.Vaxart Provides Business Update and Reports Second Quarter 2024 Financial ResultsNASDAQ:VXRTVaxart Inc
02/08/202414:00GlobeNewswire Inc.Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8NASDAQ:VXRTVaxart Inc
17/06/202422:05GlobeNewswire Inc.Vaxart Provides Business UpdateNASDAQ:VXRTVaxart Inc
14/06/202401:07GlobeNewswire Inc.Vaxart Announces $40 Million Underwritten Offering of Common StockNASDAQ:VXRTVaxart Inc
13/06/202422:15GlobeNewswire Inc.Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine CandidateNASDAQ:VXRTVaxart Inc
13/05/202422:01GlobeNewswire Inc.Vaxart Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:VXRTVaxart Inc
13/05/202413:10IH Market NewsU.S. Futures Climb Amid High Expectations for Inflation Data; Global Markets Show Mixed ReactionsNASDAQ:VXRTVaxart Inc
07/05/202414:00GlobeNewswire Inc.Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13NASDAQ:VXRTVaxart Inc
30/04/202414:00GlobeNewswire Inc.Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating MothersNASDAQ:VXRTVaxart Inc
27/03/202413:00GlobeNewswire Inc.Vaxart to Present at World Vaccine Congress Washington 2024 on April 3NASDAQ:VXRTVaxart Inc
14/03/202421:01GlobeNewswire Inc.Vaxart Provides Business Update and Reports Full Year 2023 Financial ResultsNASDAQ:VXRTVaxart Inc
14/03/202412:41IH Market NewsU.S. Stock Futures Rise Ahead Of PPI and Retail Sales; Oil Prices ClimbNASDAQ:VXRTVaxart Inc
07/03/202414:00GlobeNewswire Inc.Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14NASDAQ:VXRTVaxart Inc
06/03/202414:00GlobeNewswire Inc.Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and DirectorNASDAQ:VXRTVaxart Inc
13/02/202423:16Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VXRTVaxart Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:VXRT

La tua Cronologia

COIN
LATXUSD
LatiumX
AQSE
EDVD.GB
State Street Global Advi...
BIT
S32117
Societe Generale Effekten
BIT
F39327
Vontobel Financial Produ...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network